HHS Announces First 10 Drugs Eligible for Medicare Price Negotiations

CMS headquarters
CMS issued the final rule to implement a $9 billion lump sum payment to 340B hospitals for previous illegal cuts between 2018 and 2021.
The Department of Health and Human Services (HHS) today announced the first 10 prescription drugs eligible for Medicare price negotiations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development

AstraZeneca headquarters
The state of Louisiana and a coalition of community health centers urged a federal district court to dismiss AstraZeneca's lawsuit against a state contract pharmacy law.
Drugmaker AstraZeneca sued the federal government to block Medicare drug price negotiations on Friday, just days before the government announced [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Appeals Court Schedules Arguments in Challenge to Arkansas Contract Pharmacy Law

340B state legislation map
Two states have laws protecting 340B contract pharmacy arrangements and two others have passed 340B reporting requirements.
A federal appeals court has scheduled oral arguments for September in a case challenging Arkansas’ protections for 340B providers’ contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Drug Makers Post Manufacturer Notices for 340B Overcharges

Manufacturer notices
Meitheal Pharmaceuticals and Purdue Pharma are each sending 340B covered entities refunds for overcharges totaling $100 or more.
Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law

AstraZeneca headquarters
The state of Louisiana and a coalition of community health centers urged a federal district court to dismiss AstraZeneca's lawsuit against a state contract pharmacy law.
Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds

Health Services Research study
A Health Services Research study with funding from a government agency suggested the 340B program does not improve hospital inpatient care quality.
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Enforceability of State Contract Pharmacy Laws Uncertain Amid Legal Challenges

Louisiana capitol
PhRMA has asked a federal district judge to block Louisiana's 340B contract pharmacy law, Act 358, which took effect Aug. 1.
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program

GAO 340B
GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Merck Loosens 340B Contract Pharmacy Restrictions in Two States as Louisiana Law Takes Effect

Merck
Merck is the first drug manufacturer to announce it is issuing refunds to 340B providers in 2024.
Drug manufacturer Merck recently loosened its 340B program contract pharmacy restrictions in Louisiana and Arkansas just before Louisiana’s law protecting [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live